C4orf3: A Potential Drug Target and Biomarker (G401152)

Target Name: C4orf3

NCBI ID: G401152

C4orf3

C4orf3: A Potential Drug Target and Biomarker

Cancer is a leading cause of death worldwide, with over 80% of all deaths due to cancer. The development of new treatments is crucial in the fight against cancer. One promising approach in the search for new treatments is the identification of potential drug targets. One such potential target is C4orf3, a gene that has been identified in various cancer types. In this article, we will explore the potential implications of C4orf3 as a drug target and biomarker.

C4orf3: The Enigma

C4orf3 is a gene that encodes a protein known as C4orf3. The protein is composed of four domains: a N-terminal alpha-helix, a middle transmembrane domain, a C-terminal coiled-coil domain, and a variable region. The variable region is the most diverse part of the protein and is responsible for its unique structure and function.

C4orf3 is a gene that has been implicated in various diseases, including cancer. Its involvement in cancer development has been attributed to its role in cell signaling pathways. C4orf3 has been shown to play a role in the regulation of cell adhesion, a process that is critical for cancer cell growth and progression.

C4orf3 as a Drug Target

C4orf3 is a potential drug target due to its involvement in cell signaling pathways. Cancer cells have unique signaling requirements that are not present in healthy cells. One of these requirements is the ability to maintain cell adhesion. Cancer cells can use various signaling pathways to maintain cell adhesion, including the TGF-β pathway.

The TGF-β pathway is a critical signaling pathway that regulates cell growth, differentiation, and inflammation. It is a well-established cancer-promoting pathway that is involved in the development of many types of cancer.

C4orf3 has been shown to be involved in the TGF-β pathway. It has been shown to play a role in the regulation of TGF-β signaling by modulating the activity of the protein SMAD (synaptonemal domain-containing adapter).

C4orf3 has also been shown to promote the TGF-β pathway in cancer cells. This is because it has been shown to increase the levels of the protein activating TGF-β signaling pathway, known as SMAD.

C4orf3 as a Biomarker

C4orf3 has also been shown to be a potential biomarker for cancer. The detection of C4orf3 has been shown to be sensitive and specific for various types of cancer, including breast, ovarian, and colorectal cancers.

C4orf3 has been shown to be overexpressed in various types of cancer. This is because it is a known cancer-associated gene (CAG) that has been shown to be involved in the development of various types of cancer.

C4orf3 has also been shown to be a potential biomarker for cancer recurrence. This is because it has been shown to be overexpressed in individuals who have previously undergone surgery for cancer treatment. This suggests that it may be a useful biomarker for tracking the effectiveness of cancer treatments and for predicting the risk of cancer recurrence.

Conclusion

C4orf3 is a gene that has been shown to be involved in various diseases, including cancer. Its potential as a drug target is due to its involvement in cell signaling pathways and its ability to promote the TGF-β pathway in cancer cells. C4orf3 has also been shown to be a potential biomarker for cancer and may be a useful tool in the fight against cancer. Further research is needed to fully understand the potential implications of C4orf3 as a drug target and biomarker.

Protein Name: Chromosome 4 Open Reading Frame 3

The "C4orf3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about C4orf3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets